Scilex Holding (SCLX) Research & Development (2022 - 2026)
Scilex Holding (SCLX) recorded quarterly Research & Development of $3.2 million in Q1 2026, down 60.7% quarter-over-quarter from $8.2 million in Q4 2025, and up 30.7% on a YoY basis from $2.5 million in Q1 2025.
Scilex Holding (SCLX) Research & Development (2022 - 2026) Analysis & Trends
Scilex Holding's Research & Development history runs 5 years deep, the most recent figure standing at $3.2 million for Q1 2026.
- In Q1 2026, Research & Development rose 30.7% year-over-year to $3.2 million; the TTM figure through Mar 2026 stood at $21.5 million (up 138.78% YoY), while the FY2025 annual figure was $20.7 million, up 114.81% from the prior year.
- Research & Development was $3.2 million for Q1 2026 at Scilex Holding, down from $8.2 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $8.2 million in Q4 2025 to a low of $1.2 million in Q3 2022.
- Historically, Research & Development has averaged $3.3 million across 5 years, with a median of $2.7 million in 2023.
- The sharpest annual moves came in 2024 and 2025: Research & Development tumbled 42.31% in 2024, then jumped 274.68% in 2025.
- A 5-year view of Research & Development shows it stood at $2.6 million in 2022, then grew by 5.28% to $2.7 million in 2023, then dropped by 20.26% to $2.2 million in 2024, then surged by 274.68% to $8.2 million in 2025, then sank by 60.7% to $3.2 million in 2026.
- The last three Research & Development figures came in at $3.2 million (Q1 2026), $8.2 million (Q4 2025), and $3.9 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,134,969.93 Bn | 92,134,964.97 Bn | 7.76 Bn | -2.28 Bn |
| 2 | Eli Lilly | 1,027.45 Bn | 1,022.17 Bn | 16.22 Bn | 3.51 Bn |
| 3 | Johnson & Johnson | 559.08 Bn | 537.03 Bn | 15.96 Bn | 3.53 Bn |
| 4 | AbbVie | 394.75 Bn | 385.40 Bn | 10.78 Bn | 2.47 Bn |
| 5 | Merck | 295.12 Bn | 289.47 Bn | 12.09 Bn | 12.59 Bn |
| 6 | Amgen | 186.65 Bn | 174.61 Bn | 5.87 Bn | 1.72 Bn |
| 7 | Gilead Sciences | 159.22 Bn | 151.50 Bn | 5.52 Bn | 1.37 Bn |
| 8 | Pfizer | 146.00 Bn | 133.23 Bn | -1.21 Bn | 2.49 Bn |
| 9 | Bristol Myers Squibb | 113.22 Bn | 102.77 Bn | 8.07 Bn | 2.65 Bn |
| 10 | Scilex Holding | 48.31 Mn | -101.62 Mn | 4.15 Mn | 3.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.21 Mn |
| Dec 31, 2025 | 8.17 Mn |
| Sep 30, 2025 | 3.90 Mn |
| Jun 30, 2025 | 6.19 Mn |
| Mar 31, 2025 | 2.46 Mn |
| Dec 31, 2024 | 2.18 Mn |
| Sep 30, 2024 | 2.35 Mn |
| Jun 30, 2024 | 2.00 Mn |
| Mar 31, 2024 | 3.11 Mn |
| Dec 31, 2023 | 2.73 Mn |
| Sep 30, 2023 | 4.07 Mn |
| Jun 30, 2023 | 3.20 Mn |
| Mar 31, 2023 | 2.74 Mn |
| Dec 31, 2022 | 2.60 Mn |
| Sep 30, 2022 | 1.24 Mn |
| Jun 30, 2022 | 2.59 Mn |
| Mar 31, 2022 | 2.63 Mn |